Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jan;47(1):31-43.
doi: 10.1177/0300060518816884. Epub 2018 Dec 16.

Intravitreal fluocinolone acetonide implant (ILUVIEN®) for diabetic macular oedema: a literature review

Horace Massa  1   2 , Anindyt M Nagar  3   2 , Athanasios Vergados  3 , Panagiotis Dadoukis  3 , Sudeshna Patra  3 , Georgios D Panos  3
Affiliations
Review

Intravitreal fluocinolone acetonide implant (ILUVIEN®) for diabetic macular oedema: a literature review

Horace Massa et al. J Int Med Res. 2019 Jan.

Erratum in

  • Erratum.
    [No authors listed] [No authors listed] J Int Med Res. 2019 Feb;47(2):1099. doi: 10.1177/0300060519829969. Epub 2019 Jan 30. J Int Med Res. 2019. PMID: 30700209 Free PMC article. No abstract available.

Abstract

Diabetic macular oedema (DMO) is a common complication of diabetic retinopathy and may lead to severe visual loss. In this review, we describe the pathophysiology of DMO and review current therapeutic options such as macular laser photocoagulation, anti-vascular endothelial growth factor agents, and steroid implants with a focus on the new fluocinolone acetonide implant, ILUVIEN®. The results of the Fluocinolone Acetonide in Diabetic Macular Edema (FAME) studies are also presented together with the results of real-world studies to support the clinical use of ILUVIEN® in achieving efficient resolution of DMO and improving vision and macular anatomy in this challenging group of patients.

Keywords: Diabetic macular oedema; ILUVIEN; anti-VEGF agents; diabetes; diabetic retinopathy; fluocinolone acetonide; intravitreal injections; steroid implant.

PubMed Disclaimer

References

    1. Butt F, Khan K, Chaudhry S, et al. Electronic Patient records to identify patients in the united kingdom with diabetic macular oedema suitable for ILUVIEN((R)) (fluocinolone acetonide). Ophthalmol Ther 2016; 5: 81–94. - PMC - PubMed
    1. Lobo C, Pires I and Cuncha-Vaz J. Diabetic macular edema. In: Bernardes R, Cuncha-Vaz J (eds) Optical Coherence Tomography: A Clinical and Technical Update. Berlin: Spinger Verlag, 2012, pp.1–21.
    1. Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 2012; 35: 556–564. - PMC - PubMed
    1. Das A, McGuire PG, Rangasamy S. Diabetic macular edema: pathophysiology and novel therapeutic targets. Ophthalmology 2015; 122: 1375–1394. - PubMed
    1. Klein R, Klein BE, Moss SE, et al. The wisconsin epidemiologic study of diabetic retinopathy. XV. The long-term incidence of macular edema. Ophthalmology 1995; 102: 7–16. - PubMed

MeSH terms